Relay Therapeutics is trading 4.7% down at $18.48; the precise cause of the decline remains unclear.
- No clear company-specific announcement or catalyst dated October 6 was identified; available company-news listings point to earlier updates.
- Supplied sector context points to broad biotechnology weakness, while major market indices are higher.
- Available live XBI information does not confirm a 2.5% sector decline, leaving the sector explanation uncertain.